More than two-thirds of oral cancer cases are diagnosed in the later stages.* Not only do these patients face a lower chance of survival, but treatment in the later stages is often highly disfiguring and debilitating. At Vigilant Biosciences we are dedicated to saving lives by providing world-class early detection solutions for cancer. https://lnkd.in/edi5xHPj #oralcancer #earlydetection #vigilantbiosciences
关于我们
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of cancer. The BeVigilant? OraFusion System aids clinicians with identifying patients at risk for oral cancers. It is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant? OraFusion System, the first and only technology that measures tumor-initiating and stem cell associated biomarkers – markers clinically validated to be associated with oral cancer – was developed to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant? OraFusion System uses a simple collection method that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant? OraFusion System is CE Marked and available in select markets outside of the United States. The BeVigilant? OraFusion System is not available for sale in the U.S. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer
- 网站
-
https://www.vigilantbiosciences.com
Vigilant Biosciences, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Lakeway ，TX
- 类型
- 私人持股
- 创立
- 2011
- 领域
- Biotechnology、Oncology和Diagnostics
地点
-
主要
获取路线
1008 Ranch Road 620
Suite 204
US，TX，Lakeway ，78734
Vigilant Biosciences, Inc.员工
动态
-
Earlier this year, the BeVigilant? OraFusion? System was awarded the Breakthrough Device Designation from the FDA. As the first of its kind, the BeVigilant? OraFusion System uses patented technology to aid clinicians in the assessment of mucosal oral abnormalities which may assist in the early detection of oral cancer. Learn more about the significance of this designation: https://lnkd.in/e2NB4sTM?
Vigilant Biosciences Receives Breakthrough Device Designation from FDA for Point-of-Care Test to Aid in the Early Detection of Oral Cancer - Vigilant Biosciences
https://vigilantbiosciences.com
-
Despite decades of research and clinical innovation, most oral cancer cases are still diagnosed in later stages. While late-stage symptom onset is a major cause, there are steps both providers and patients can take to catch the disease early for better outcomes. Read more: https://lnkd.in/eWqf-9cn #oralcancer #earlydetection #vigilantbiosciences
Challenges in the Early Detection of Oral Cancer - Vigilant Biosciences
https://vigilantbiosciences.com